Overview

Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients

Status:
Completed
Trial end date:
2019-09-18
Target enrollment:
Participant gender:
Summary
Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug
Details
Lead Sponsor:
PharmaMar
Treatments:
Trabectedin